[
  {
    "ts": null,
    "headline": "Stryker Corp. stock underperforms Thursday when compared to competitors",
    "summary": "Stryker Corp. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bf994bba268eeb9d4fdd2e59c734d09c12041bb7aba3f624a111ff92310a70c2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626340,
      "headline": "Stryker Corp. stock underperforms Thursday when compared to competitors",
      "id": 132067348,
      "image": "",
      "related": "SYK",
      "source": "MarketWatch",
      "summary": "Stryker Corp. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bf994bba268eeb9d4fdd2e59c734d09c12041bb7aba3f624a111ff92310a70c2"
    }
  },
  {
    "ts": null,
    "headline": "Stryker price target raised to $409 from $380 at Truist",
    "summary": "Truist analyst Richard Newitter raised the firm’s price target on Stryker (SYK) to $409 from $380 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth,",
    "url": "https://finnhub.io/api/news?id=8bed27a3df72404953a6f933e8c77d42bf8f0a047b0a8e18a1774deae97a17c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734611841,
      "headline": "Stryker price target raised to $409 from $380 at Truist",
      "id": 132053173,
      "image": "https://media.zenfs.com/en/tipranks_452/38a68defd725ddd544390055e985cfb8",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Truist analyst Richard Newitter raised the firm’s price target on Stryker (SYK) to $409 from $380 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth,",
      "url": "https://finnhub.io/api/news?id=8bed27a3df72404953a6f933e8c77d42bf8f0a047b0a8e18a1774deae97a17c5"
    }
  },
  {
    "ts": null,
    "headline": "The Gabelli Global Growth Fund Q3 2024 Commentary",
    "summary": "The Gabelli Global Growth Fund returned +2.7% during the third quarter, compared with a +5.5% return for the S&P 500. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=6f58ee1ef1bed1da52584073b3a3a7913938bfdcb0c10f1f2590a057800df21c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734572400,
      "headline": "The Gabelli Global Growth Fund Q3 2024 Commentary",
      "id": 132045592,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2151433053/image_2151433053.jpg?io=getty-c-w1536",
      "related": "SYK",
      "source": "SeekingAlpha",
      "summary": "The Gabelli Global Growth Fund returned +2.7% during the third quarter, compared with a +5.5% return for the S&P 500. Click here to read the full commentary.  ",
      "url": "https://finnhub.io/api/news?id=6f58ee1ef1bed1da52584073b3a3a7913938bfdcb0c10f1f2590a057800df21c"
    }
  }
]